StratDeck

Two stocks in Healthcare

Alcon vs Novartis: profit, growth, debt and price compared

Novartis is stronger on 4 of 7 figures: profit margin, price for its expected profit, dividend and price trend. Alcon is stronger on 2: debt and analysts' view.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Alcon and Novartis side by side
AlconALC.SWNovartisNOVN.SW
Net margin6.1%Stronger: 17.5%
Revenue growth, past year+4.70%+4.70%
Debt to equityStronger: 24.6%128.6%
Forward P/E17.3×Stronger: 15.9×
Dividend yield0.45%Stronger: 2.78%
AnalystsStronger: Buy · 17Hold · 22
From its 200-day average+7.2%Stronger: +9.2%

Share price over the past year

  • Alcon+1.5%
  • Novartis+24.3%

17 Nov 202518 Nov 2026

Alcon or Novartis: which is stronger?

  • NOVN.SW

    Which is more profitable?

    Novartis keeps more of each sale as profit: 17.5% against 6.1%.

  • Which is growing its sales faster?

    Both grew their sales at the same pace: +4.70% over the past year.

  • ALC.SW

    Which has borrowed less?

    Alcon has borrowed less: its debt is 24.6% of what its shareholders own, against 128.6% for Novartis.

  • NOVN.SW

    Which costs less for the profit it is expected to make?

    Novartis costs less for the profit it is expected to make: 15.9× its forward earnings, against 17.3×.

  • NOVN.SW

    Which pays more in dividends?

    Novartis pays more back in dividends for what a share costs: 2.78% a year, against 0.45%.

  • ALC.SW

    Which do analysts rate higher?

    Analysts are warmer on Alcon: Buy, against Hold for Novartis.

  • NOVN.SW

    Which is in the stronger price trend?

    Novartis' price is in the stronger trend: 9.2% above its 200-day average, against 7.2% above.

What each company does

ALC.SWAlcon

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide.

Reports results on 23 February 2027

NOVN.SWNovartis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.